GB2579480B - Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient - Google Patents
Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient Download PDFInfo
- Publication number
- GB2579480B GB2579480B GB2001444.5A GB202001444A GB2579480B GB 2579480 B GB2579480 B GB 2579480B GB 202001444 A GB202001444 A GB 202001444A GB 2579480 B GB2579480 B GB 2579480B
- Authority
- GB
- United Kingdom
- Prior art keywords
- preventing
- composition
- active ingredient
- treating cancer
- based derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000004480 active ingredient Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170103561A KR101924801B1 (en) | 2017-08-16 | 2017-08-16 | Composition for preventing or treating cancer comprising triazolopyridine derivatives |
| PCT/KR2018/002502 WO2019035522A1 (en) | 2017-08-16 | 2018-02-28 | Composition for preventing or treating cancer containing triazolopyridine-based derivative as active ingredient |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB202001444D0 GB202001444D0 (en) | 2020-03-18 |
| GB2579480A GB2579480A (en) | 2020-06-24 |
| GB2579480B true GB2579480B (en) | 2022-04-27 |
Family
ID=64668937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2001444.5A Active GB2579480B (en) | 2017-08-16 | 2018-02-28 | Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR101924801B1 (en) |
| DE (1) | DE112018004197T5 (en) |
| GB (1) | GB2579480B (en) |
| WO (1) | WO2019035522A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200335182A1 (en) * | 2019-04-16 | 2020-10-22 | Uratim Ltd. | Method and apparatus for facilitating the binding of biological macromolecules with the use of gluing molecular agents with applications in RAS mutations and related conditions |
| KR102790276B1 (en) * | 2021-11-18 | 2025-04-04 | 한국원자력의학원 | Compound for inhibiting tankyrase and medical use thereof |
| KR102854346B1 (en) * | 2023-02-02 | 2025-09-04 | 한국원자력의학원 | Composition for preventing or treating cancer containing aryl-piperidine derivatives |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013040215A1 (en) * | 2011-09-14 | 2013-03-21 | Samumed, Llc | Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
| WO2015143380A1 (en) * | 2014-03-20 | 2015-09-24 | Samumed, Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2840454T3 (en) | 2009-12-31 | 2021-07-06 | Hutchison Medipharma Ltd | Synthetic intermediate useful in the preparation of triazolopyridine c-Met inhibitors |
| JP6428114B2 (en) | 2014-09-30 | 2018-11-28 | ブラザー工業株式会社 | Liquid consumption device |
| JP6706250B2 (en) | 2015-04-20 | 2020-06-03 | 武田薬品工業株式会社 | Heterocyclic compound |
-
2017
- 2017-08-16 KR KR1020170103561A patent/KR101924801B1/en active Active
-
2018
- 2018-02-28 GB GB2001444.5A patent/GB2579480B/en active Active
- 2018-02-28 DE DE112018004197.2T patent/DE112018004197T5/en active Pending
- 2018-02-28 WO PCT/KR2018/002502 patent/WO2019035522A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013040215A1 (en) * | 2011-09-14 | 2013-03-21 | Samumed, Llc | Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
| WO2015143380A1 (en) * | 2014-03-20 | 2015-09-24 | Samumed, Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
Non-Patent Citations (3)
| Title |
|---|
| Chemical Abstract Compound, STN express. RN 1223727-82-9 (14 May 2010) See the chemical formulas * |
| Chemical Abstract Compound, STN express. RN 1278246-01-7 (10 April 2011) See the chemical formulas * |
| Chemical Abstract Compound, STN express.RN 1293587-55-9 (12 May 2011) * See the chemical formulas. * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101924801B1 (en) | 2018-12-04 |
| WO2019035522A1 (en) | 2019-02-21 |
| DE112018004197T5 (en) | 2020-04-30 |
| GB202001444D0 (en) | 2020-03-18 |
| GB2579480A (en) | 2020-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3431105T (en) | Medicinal composition for treating cancer | |
| EP3263135A4 (en) | Pharmaceutical composition for treating cancer comprising microrna as active ingredient | |
| IL267132B (en) | Pharmaceutical composition for preventing or treating cancer, comprising tetraarsenic hexoxide crystalline polymorph | |
| EP3659611A4 (en) | Composition for preventing or treating osteoporosis containing exosomes extracted from stem cells as active ingredient | |
| IL261196A (en) | Pharmaceutical composition for treatment of cancer, containing polyphenol compound as active ingredient | |
| IL263697A (en) | Compounds, compositions and methods for prevention and/or treatment of cancer | |
| SG11201605868XA (en) | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient | |
| EP3266317A4 (en) | Composition for preventing, improving or treating neurological disorders, containing osmotin peptide as active ingredient | |
| IL263793A (en) | Compounds and compositions for the treatment of cancer | |
| ZA201803320B (en) | Pharmaceutical compositions for treating pain | |
| EP3689355A4 (en) | Pharmaceutical composition for preventing or treating liver cancer | |
| IL275525A (en) | Pharmaceutical composition for the treatment of cancer | |
| EP3662914A4 (en) | Composition for preventing or treating scars | |
| EP2982378A4 (en) | Composition for preventing or treating sepsis or septic shock, comprising adk protein as active ingredient | |
| SG10201912046VA (en) | Pharmaceutical composition for preventing or treating regulatory t cell-mediated diseases | |
| SG11201704766UA (en) | Antibacterial composition containing adk protein as active ingredient, or composition for preventing or treating septicemia | |
| GB2579480B (en) | Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient | |
| EP3284464A4 (en) | Composition for preventing and treating pancreatitis containing naphthoquinone-based compound as active ingredient | |
| EP3162803A4 (en) | New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient | |
| EP3148570A4 (en) | Pharmaceutical composition for preventing or treating skin rash | |
| EP3398608A4 (en) | Pharmaceutical composition for preventing and treating cancer or cancer metastasis, containing pstl1 protein as active ingredient | |
| PL3236961T3 (en) | Pharmaceutical composition for preventing or treating cancer | |
| EP3260121A4 (en) | Composition for preventing, alleviating or treating metabolic diseases, containing amodiaquine as active ingredient | |
| EP3290051A4 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| PL3773641T3 (en) | Topical pharmaceutical compositions for treating skin conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 789A | Request for publication of translation (sect. 89(a)/1977) |
Ref document number: 2019035522 Country of ref document: WO |